Record-Breaking Price Movement
On 27 August 2026, Entero Healthcare Solutions Ltd’s stock price surged to ₹1,670.25, surpassing its previous 52-week high of ₹1,666.40 by a margin of 0.23%. This marks the highest valuation the stock has ever achieved, underscoring the company’s upward trajectory in the market. The stock outperformed the broader Sensex index, which declined by 0.15% on the same day, while Entero Healthcare advanced by 1.43%.
The stock has demonstrated remarkable momentum, gaining for six consecutive trading days and delivering an 18.99% return over this period. It has consistently traded above key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a strong bullish trend.
Market and Sector Outperformance
Entero Healthcare’s performance has notably outpaced its retailing sector peers. Over the past week, the stock rose by 18.53%, outperforming the sector by 0.51%. Its one-month return stands at 31.22%, while the three-month gain is an impressive 40.65%. These figures contrast sharply with the Sensex’s modest 0.68% and 1.96% returns over the same periods, respectively.
Year-to-date, the stock has delivered a remarkable 62.82% return, significantly exceeding the Sensex’s decline of 9.23%. Over the last year, Entero Healthcare generated a 37.91% return compared to the BSE500’s 3.01%, highlighting its market-beating performance.
Financial Strength and Growth Metrics
The company’s robust financial health underpins this market success. Entero Healthcare Solutions Ltd has demonstrated strong long-term growth, with net sales expanding at an annual compound growth rate of 31.53% and operating profit increasing by 71.45% over the past five years. The latest quarterly results for June 2026 reinforce this trend, with net sales reaching a record ₹1,940.50 crores and PBDIT hitting ₹97.00 crores, both the highest in the company’s history.
Net profit grew by 15.33% in the same quarter, marking the tenth consecutive quarter of positive results. The company’s return on capital employed (ROCE) for the half-year period stands at a peak of 10.23%, reflecting efficient utilisation of capital.
Valuation and Quality Assessment
Entero Healthcare is classified as a small-cap company with a Mojo Score of 74.0 and a current Mojo Grade of Buy, revised from Strong Buy on 11 August 2026. The stock trades at a price-to-earnings (P/E) ratio of 54 times trailing twelve months earnings, and a price-to-book value of 4.22 times. Its enterprise value to capital employed ratio is 3.62 times, indicating a fair valuation relative to its capital base.
The company’s PEG ratio stands at 1.86, reflecting a balance between growth and valuation. Despite trading at a premium compared to peers’ historical averages, the stock’s valuation is supported by consistent earnings growth and strong operational metrics.
Quality metrics indicate an average overall grade, with excellent growth and good capital structure. The company maintains low leverage, with an average net debt to equity ratio of 0.23 and a moderate debt to EBITDA ratio of 2.54 times. Management risk is assessed as average, while growth remains a standout feature.
Technical Analysis and Trading Activity
Technical indicators confirm a bullish trend that began on 11 August 2026 at a price of ₹1,427.30. Weekly and monthly momentum indicators such as MACD and Bollinger Bands are bullish, while the relative strength index (RSI) shows no immediate signal on the weekly chart and a bearish signal on the monthly chart. The stock’s immediate support level is ₹944.00, coinciding with its 52-week low, while resistance levels are identified at ₹1,379.43 (20-day moving average), ₹1,236.94 (100-day moving average), and ₹1,163.85 (200-day moving average).
Delivery volumes have surged, with a 1-month delivery change of 307.17% and a 1-day delivery change of 65.23% compared to the 5-day average, indicating strong trading interest and liquidity.
Institutional Holding Trends
Institutional investors currently hold 19.85% of the company’s shares, though their stake has decreased by 0.8% over the previous quarter. This moderate level of institutional participation reflects a cautious stance among larger investors despite the company’s strong fundamentals and market performance.
Summary of Key Financial Highlights
Recent quarterly figures highlight the company’s operational strength:
- Highest quarterly net sales of ₹1,940.50 crores
- Record quarterly PBDIT of ₹97.00 crores
- Operating profit margin at 5.00% for the quarter
- Profit before tax excluding other income grew by 52.4% to ₹64.11 crores
- Highest quarterly PAT of ₹38.16 crores
- Quarterly EPS at ₹8.77, the highest recorded
Conclusion
Entero Healthcare Solutions Ltd’s achievement of an all-time high stock price on 27 August 2026 is a testament to its sustained financial growth, operational efficiency, and positive market sentiment. The company’s consistent quarterly performance, strong sales growth, and solid return metrics have propelled it ahead of sector peers and the broader market indices. While institutional participation has slightly declined, the stock’s technical and fundamental indicators remain robust, supporting its current valuation and market position within the retailing sector.
